home / stock / msclf / msclf short
Short Information | iCo Therapeutics (OTCMKTS:MSCLF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 506,388 |
Total Actual Volume | 585,439 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 18 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 25,319 |
Average Short Percentage | 78.00% |
Is there a MSCLF Short Squeeze or Breakout about to happen?
See the MSCLF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-02-2024 | $0.38493 | $0.3956 | $0.41 | $0.38493 | 7,000 | 5,350 | 76.43% |
07-01-2024 | $0.4342 | $0.4076 | $0.4342 | $0.4076 | 1,600 | 1,600 | 100% |
06-28-2024 | $0.4331 | $0.4431 | $0.4431 | $0.40155 | 7,650 | 6,150 | 80.39% |
06-27-2024 | $0.4431 | $0.40655 | $0.4431 | $0.3877 | 1,791 | 1,791 | 100% |
06-26-2024 | $0.3877 | $0.3877 | $0.3891 | $0.3877 | 22,515 | 7,515 | 33.38% |
06-25-2024 | $0 | $0.44874 | $0 | $0 | 300,000 | 300,000 | 100% |
06-24-2024 | $0.4329 | $0.44874 | $0.44874 | $0.4329 | 2,200 | 1,200 | 54.55% |
06-21-2024 | $0.4721 | $0.47 | $0.578 | $0.44135 | 114,245 | 75,500 | 66.09% |
06-18-2024 | $0.3853 | $0.38845 | $0.38845 | $0.3853 | 3,050 | 2,000 | 65.57% |
06-12-2024 | $0.42285 | $0.4139 | $0.4229 | $0.4139 | 10,281 | 9,000 | 87.54% |
05-31-2024 | $0.3776 | $0.3776 | $0.37785 | $0.3776 | 15,000 | 10,000 | 66.67% |
05-30-2024 | $0.38 | $0.3833 | $0.3833 | $0.38 | 56,400 | 56,400 | 100% |
05-28-2024 | $0.3568 | $0.36 | $0.36 | $0.3568 | 4,850 | 2,700 | 55.67% |
05-23-2024 | $0.3474 | $0.3251 | $0.35 | $0.32 | 27,950 | 19,000 | 67.98% |
05-21-2024 | $0.34175 | $0.34175 | $0.34175 | $0.34175 | 2,025 | 2,000 | 98.77% |
05-20-2024 | $0.368 | $0.368 | $0.368 | $0.368 | 2,000 | 2,000 | 100% |
05-17-2024 | $0.35 | $0.35 | $0.3561 | $0.35 | 2,900 | 200 | 6.9% |
05-15-2024 | $0.368 | $0.368 | $0.368 | $0.368 | 1,000 | 1,000 | 100% |
05-13-2024 | $0.3404 | $0.3404 | $0.3404 | $0.3404 | 2,777 | 2,777 | 100% |
05-10-2024 | $0.34 | $0.34 | $0.34 | $0.34 | 205 | 205 | 100% |
News, Short Squeeze, Breakout and More Instantly...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSC...